查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2024424

血紅蛋白疾病市場報告：按類型、治療方法、檢測類型、最終用戶和地區分類（2026-2034 年）

Hemoglobinopathies Market Report by Type, Treatment, Test Type, End User, and Region 2026-2034
出版日期: | 出版商: IMARC | 英文 137 Pages | 商品交期: 2-3個工作天內

價格

2025年全球血紅素疾病市場規模達119億美元。展望未來，IMARC Group預測，到2034年，該市場規模將達到233億美元，2026年至2034年的複合年成長率為7.52%。市場成長的主要促進因素包括製藥公司、醫療服務提供者和研究機構之間策略聯盟和夥伴關係的日益增多，個人化醫療的興起，以及監管支持和有利的報銷政策。

血紅蛋白疾病是一組影響血紅蛋白分子的遺傳性疾病，而血紅蛋白分子對於紅血球的正常功能至關重要，而紅血球負責將氧氣輸送到全身。這些疾病主要分為兩類：地中海貧血和異常血紅素變異，例如鐮狀貧血。地中海貧血是由基因突變引起的，這些突變會減少構成血紅蛋白的任何一種珠蛋白鏈的生成，導致血紅蛋白失衡並最終導致貧血。鐮狀貧血等疾病是由基因突變引起的，這些突變會導致血紅蛋白分子本身的形狀或功能異常。異常的形狀會導致紅血球硬化，使其難以通過狹窄的血管，進而影響氧氣供應。這些疾病通常具有遺傳性，並可引起多種症狀，從輕微的疲勞和虛弱到極端情況下的器官損傷。

公眾意識的提高是全球市場的主要驅動力。專注於血紅蛋白疾病的組織在遊說政策變革、資金籌措和改善患者照護方面日益有效。它們在公眾意識宣傳活動中也發揮著至關重要的作用，這些活動增加了早期診斷和治療的機會。隨著醫療保健體系的日益完善和普及，診斷和治療血紅蛋白疾病等特殊疾病的能力也不斷提高。新的診所和醫院正在採用先進的診斷技術，從而為更廣泛的患者群體提供醫療保健服務。此外，製藥公司、醫療保健機構和研究機構之間的策略合作與夥伴關係也促進了血紅蛋白疾病產業的成長。此外，對個人化醫療的日益重視是另一個對血紅素疾病市場產生正面影響的因素。個人化醫療是指根據每位患者的個別特徵量身訂做治療方案。向個人化醫療的轉變正在影響對專業診斷測試和治療的需求，從而進一步推動市場成長。此外，監管支持和優惠的報銷政策也為市場前景帶來了光明。

血紅素疾病市場趨勢及促進因素：

血紅素疾病盛行率增加

推動血紅蛋白疾病產業發展的最重要因素之一是血紅蛋白疾病（包括鐮狀細胞貧血、地中海貧血和其他罕見突變）盛行率的上升。雖然這些疾病在某些種族和地區更為常見，但全球人口流動趨勢導致其在更廣泛的人群中被發現。即使在歷史上發病率較低的國家，病例也在增加，因此需要改善醫療基礎設施來應對這些疾病。隨著人們對血紅素疾病的認知和診斷率的提高，對專門的治療、診斷和管理方案的需求也隨之成長。此外，接受過識別和治療血紅蛋白疾病培訓的醫療專業人員數量的增加也進一步推動了市場成長。所有這些因素都促使人們對血紅蛋白疾病專用藥物、診斷設備、基因檢測套組和專業醫療服務的需求不斷成長，推動了產業發展。

診斷和治療方面的技術進步

血紅蛋白疾病產業的另一個關鍵促進因素是診斷和治療方法技術的進步。透過新生兒篩檢和包括高效液相層析(HPLC) 和分子技術在內的先進診斷工具進行早期診斷，正在改善疾病管理。此外，基因療法、CRISPR 技術以及改良藥物製劑等治療方法的進步，也為更有效地治療血紅蛋白疾病鋪平了道路。這些創新不僅改善了病患的治療效果，也激勵市場相關人員加大研發投入。隨著技術的不斷發展，預計未來將出現更精準、更快速的診斷工具以及潛在的根治性治療方法，這將進一步推動產業需求的成長和發展。

政府措施和資金

政府措施也是血紅素疾病產業的重要市場驅動力。世界各國政府日益認知到血紅蛋白疾病對公共衛生的影響，並制定有針對性的計畫來應對這些疾病。這些舉措包括資助研究、進行宣傳宣傳活動以及將血紅蛋白疾病篩檢納入國家醫療保健計劃。這些措施不僅提高了診斷率，也使更多人能夠獲得治療。此外，政府也為從事治療方法研發的製藥公司和研究機構提供專案津貼和財政支援。這些舉措以及對行業的資金注入顯著促進了供需平衡，從而推動了市場成長。

目錄

第1章：序言

第2章：調查方法

  • 調查目的
  • 相關利益者
  • 數據來源
    • 主要訊息
    • 次要訊息
  • 市場估值
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章執行摘要

第4章：引言

第5章：全球血紅素疾病市場

  • 市場概覽
  • 市場表現
  • 新冠疫情的影響
  • 市場預測

第6章 市場區隔：依類型

  • 地中海型貧血
    • 主要部分
      • α地中海貧血
      • BETA-地中海型貧血
  • 鐮狀細胞貧血症
  • 其他

第7章 市場區隔：依治療方式分類

  • 輸血
  • 幹細胞移植
  • 止痛藥
  • 抗生素
  • ACE抑制劑
  • 羥基尿素
  • 其他

第8章 市場區隔：依測試類型分類

  • 紅血球計數
  • 基因檢測
  • 高效液相層析（HPLC）
  • 血紅素等電聚焦（Hb IEF）
  • 血紅素電泳（Hb ELP）
  • 血紅素溶解度試驗

第9章 市場區隔：依最終用戶分類

  • 醫院和診所
  • 診斷檢查室
  • 其他

第10章 市場區隔：依地區分類

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第11章 SWOT 分析

第12章：價值鏈分析

第13章：波特五力分析

第14章：價格分析

第15章 競爭格局

  • 市場結構
  • 主要企業
  • 主要企業簡介
    • Bio-Rad Laboratories Inc.
    • bluebird bio, Inc.
    • Bristol-Myers Squibb Company
    • CHIESI Farmaceutici SpA
    • Danaher Corporation
    • Emmaus Medical, Inc.
    • Gamida Cell
    • Medunik USA
    • Novartis AG
    • Prolong Pharmaceuticals, LLC
Product Code: SR112026A5123

The global hemoglobinopathies market size reached USD 11.9 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 23.3 Billion by 2034, exhibiting a growth rate (CAGR) of 7.52% during 2026-2034. The rising strategic collaborations and partnerships among pharmaceutical companies, healthcare providers, and research institutions, the growing shift toward personalized medicine, and the implementation of regulatory support and favorable reimbursement policies are among the key factors driving the market growth.

Hemoglobinopathies are a group of genetic disorders that affect the hemoglobin molecule, which is crucial for the proper function of red blood cells in carrying oxygen throughout the body. These disorders can be categorized mainly into two types: thalassemias and abnormal hemoglobin variants, such as sickle cell anemia. Thalassemias result from mutations that reduce the production of one of the globin chains that make up hemoglobin, leading to an imbalance and subsequent anemia. On the other hand, conditions such as sickle cell anemia are caused by mutations that lead to abnormal shapes or functions of the hemoglobin molecule itself. The abnormal shapes can cause red blood cells to become rigid, making it difficult for them to travel through small blood vessels, thereby affecting oxygen distribution. They are often inherited and can result in symptoms ranging from mild to severe, including fatigue, weakness, and in extreme cases, organ damage.

The growing public awareness majorly drives the global market. Organizations focused on hemoglobinopathies are increasingly effective at lobbying for policy changes, funding, and improved patient care. They are also crucial in educating the public, thereby increasing early diagnosis and treatment. As healthcare systems become more robust and accessible, the capability to diagnose and treat specialized conditions, such as hemoglobinopathies also increases. New clinics and hospitals are being equipped with advanced diagnostic technologies, thereby reaching a larger patient population. Along with this, strategic collaborations and partnerships among pharmaceutical companies, healthcare providers, and research institutions are also driving the growth of the hemoglobinopathies industry. In addition, the growing emphasis on personalized medicine is another factor that impacts the hemoglobinopathies market positively. Personalized medicine involves tailoring medical treatment to individual patient characteristics. The shift toward personalized medicine is influencing the demand for specialized diagnostic tests and treatments, further driving market growth. Moreover, the implementation of regulatory support and favorable reimbursement policies is creating a positive market outlook.

HEMOGLOBINOPATHIES MARKET TRENDS/DRIVERS:

Increasing prevalence of hemoglobin disorders

One of the most significant drivers propelling the hemoglobinopathies industry is the rising prevalence of hemoglobin disorders such as sickle cell anemia, thalassemias, and other rare variants. These disorders are prevalent in specific ethnic groups and geographical regions, but due to global migration patterns, they are increasingly found in a more widespread population. Countries with historically low incidence rates are now reporting more cases, necessitating improved healthcare infrastructure to manage these conditions. As awareness grows and diagnosis rates increase, there is a corresponding rise in demand for specialized treatments, diagnostics, and management plans. Additionally, more healthcare providers are being trained to recognize and treat hemoglobinopathies, further facilitating market growth. All these factors contribute to increased needs for medication, diagnostics equipment, genetic testing kits, and specialized healthcare services tailored for hemoglobinopathies, thereby driving the industry's growth.

Technological advancements in diagnosis and treatment

Another significant driver for the hemoglobinopathies industry is the technological advancements in both diagnostic methods and treatments. Earlier diagnosis through newborn screenings and sophisticated diagnostic tools including High-Performance Liquid Chromatography (HPLC) and molecular techniques have led to better management of the condition. Along with this, advancements in treatment methods, including gene therapy, CRISPR technology, and improved drug formulations, are also paving the way for more effective management of hemoglobin disorders. These innovations not only enhance patient outcomes but also provide an impetus for market players to invest in research and development. As the technology evolves, we can anticipate more accurate, quicker diagnostic tools and potentially curative therapies, driving greater demand and expansion in the industry.

Government Initiatives and Funding

Governmental efforts are also significant market drivers for the hemoglobinopathies industry. Various governments worldwide are increasingly acknowledging the public health impact of hemoglobin disorders and are setting up targeted programs to deal with them. In addition, funding for research, public awareness campaigns, and inclusion of hemoglobinopathy screening in national healthcare plans are examples of such initiatives. These steps not only increase the rate of diagnosis but also make treatments more accessible to a larger population. Special grants and financial support for pharmaceutical companies and research institutions for developing treatments are also available. Such initiatives and financial injections into the sector significantly bolster both demand and supply, facilitating market growth.

HEMOGLOBINOPATHIES INDUSTRY SEGMENTATION:

Breakup by Type:

  • Thalassemia
    • Alpha Thalassemia
    • Beta Thalassemia
  • Sickle Cell Disease
  • Others

Sickle cell disease accounts for the majority of the market share

The market for treating sickle cell disease (SCD), a type of hemoglobinopathy, is experiencing robust growth due to the rising incidence and awareness of SCD, particularly in African, Middle Eastern, and South Asian populations. Additionally, advancements in diagnostic techniques, including high-performance liquid chromatography (HPLC) and genetic screening are enabling earlier and more accurate detection, increasing the demand for targeted treatments. In addition, government initiatives have also played a pivotal role by incorporating SCD screenings in national healthcare plans and providing funding for research. In addition, the emergence of innovative treatment options such as gene therapies and CRISPR technology offer potential curative solutions, attracting significant investment in the sector. Furthermore, positive regulatory frameworks and reimbursement policies make treatments more accessible, thereby expanding the market.

Breakup by Treatment:

  • Blood Transfusion
  • Stem-cell Transplantation
  • Analgesics
  • Antibiotics
  • ACE Inhibitors
  • Hydroxyurea
  • Others

The demand for blood transfusion treatment in the hemoglobinopathies industry is primarily driven by its essential role in managing severe cases of disorders, such as thalassemia and sickle cell disease. Along with this, the increasing prevalence of these conditions amplifies the need for regular transfusions, thereby fueling market growth. In addition, technological advancements in blood screening and storage have also contributed to safer and more efficient transfusion processes. Governmental initiatives, such as organized blood donation campaigns and reimbursement policies, make this treatment more accessible and cost-effective for patients. In addition, the growing interest in stem-cell transplantation as a potentially curative treatment for hemoglobinopathies, including thalassemia and sickle cell disease is a notable market driver. Moreover, technological advancements have made these procedures safer and more effective, drawing increased investment and research focus. Governmental backing in the form of grants and regulatory approval fast-tracks also bolster this sector.

On the other hand, the growing awareness and advocacy for advanced treatment options have led to higher demand for stem-cell transplantation, further propelling market growth in the hemoglobinopathies industry. Apart from this, the demand for analgesics in the hemoglobinopathies industry is driven by chronic pain. Increasing awareness and diagnosis rates further provide a boost to this market segment. The need for antibiotics in the hemoglobinopathies industry is driven by frequent bacterial infections in patients, thereby stimulating the demand for effective treatment options. Furthermore, the market for ACE inhibitors in the hemoglobinopathies industry is propelled by their role in managing kidney complications in patients.

Breakup by Test Type:

  • Red Blood Cell (RBC) Count
  • Genetic Testing
  • High Performance Liquid Chromatography (HPLC)
  • Hemoglobin Isoelectric Focusing (Hb IEF)
  • Hemoglobin Electrophoresis (Hb ELP)
  • Hemoglobin Solubility Test

In the hemoglobinopathies industry, the market drivers for the red blood cell (RBC) count test type are significant. Hemoglobinopathies, including conditions, such as sickle cell anemia and thalassemia, necessitate frequent monitoring of RBC counts to assess disease severity and treatment efficacy. As awareness of these disorders grows, so does the demand for accurate diagnostic tools. Moreover, advancements in healthcare technology have led to more accessible and cost-effective RBC count testing methods. The combination of increased disease awareness and improved diagnostic capabilities positions the RBC count test as a critical component of the hemoglobinopathies industry, driving its market growth. Along with this, genetic testing is a key market driver in the hemoglobinopathies industry, enabling precise disease identification and personalized treatment strategies, and fostering growth and innovation.

On the other hand, high-performance liquid chromatography (HPLC) is a crucial driver in the hemoglobinopathies industry, providing precise hemoglobin analysis, enhancing diagnostics, and fostering industry advancement. Apart from this, hemoglobin isoelectric focusing (Hb IEF) plays a pivotal role in the hemoglobinopathies industry by offering precise hemoglobin analysis, driving diagnostic accuracy, and industry growth. In confluence with this, hemoglobin electrophoresis (Hb ELP) is a cornerstone in the hemoglobinopathies industry, providing precise hemoglobin analysis, driving diagnostic accuracy, and fostering industry growth. Furthermore, hemoglobin solubility testing is a critical driver in the hemoglobinopathies industry, offering efficient diagnosis and aiding in disease management, contributing to industry growth.

Breakup by End User:

  • Hospitals and Clinics
  • Diagnostics Laboratories
  • Others

Diagnostics laboratories serve as a pivotal end user in the hemoglobinopathies industry, driving growth due to their central role in disease diagnosis and management. In addition, the increasing prevalence of hemoglobinopathies worldwide necessitates a higher volume of diagnostic tests, including hemoglobin analysis and genetic testing. Furthermore, ongoing research and development efforts focus on enhancing the accuracy and efficiency of diagnostic tools, further elevating the significance of diagnostics laboratories. Their expertise and technology contribute significantly to advancing our understanding of hemoglobin disorders and tailoring treatment approaches, solidifying their status as key market drivers in this industry.

On the contrary, hospitals and clinics represent crucial end users in the hemoglobinopathies industry, actively driving growth and advancement. These healthcare facilities are frontline providers of care to individuals affected by hemoglobin disorders. The growing awareness of these conditions, coupled with an increasing patient population, leads to a higher demand for diagnostic tests, genetic counseling, and specialized treatments. Hospitals and clinics play a pivotal role in providing comprehensive care, driving the need for improved diagnostic tools and therapeutic interventions. Their prominence as end users reinforces their impact as significant market drivers in the hemoglobinopathies industry.

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

North America leads the market, accounting for the largest hemoglobinopathies market share

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

North America stands as a dynamic and influential region in the hemoglobinopathies industry, driven by the region's commitment to healthcare excellence and rigorous standards. It fuels the demand for cutting-edge diagnostic tools and therapeutic interventions. The prevalence of hemoglobin disorders, particularly sickle cell disease, within diverse populations, including African Americans and Hispanic communities, places North America at the forefront of research, diagnosis, and treatment.

Additionally, the region's robust research and development ecosystem, consisting of academic institutions, pharmaceutical companies, and biotechnology firms, fosters innovation in hemoglobinopathy diagnostics and therapies. This research-driven environment continually introduces novel diagnostic methods and treatment modalities, stimulating market growth. Furthermore, advocacy efforts and government initiatives aimed at improving healthcare access for individuals with hemoglobinopathies amplify the demand for diagnostic testing and specialized care. These initiatives include newborn screening programs and policies supporting early diagnosis and intervention.

COMPETITIVE LANDSCAPE:

The key players are investing heavily in research and development to discover new diagnostic tests, therapies, and treatment modalities. They aim to enhance the accuracy of diagnostic tools and develop innovative treatments that can improve the quality of life for individuals with hemoglobin disorders. Along with this, companies are continually developing and improving diagnostic tests for hemoglobinopathies, including advancements in techniques, such as genetic testing, high-performance liquid chromatography (HPLC), hemoglobin electrophoresis (Hb ELP), and hemoglobin isoelectric focusing (Hb IEF) is positively influencing the market. In addition, pharmaceutical companies in the hemoglobinopathies market work on the development of new therapies, including gene therapies, gene editing technologies (e.g., CRISPR), and small molecule drugs, which act as another growth-inducing factor. Furthermore, the widespread adoption of cutting-edge technologies, such as artificial intelligence and machine learning, for data analysis and improving diagnostic accuracy is contributing to the market.

The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

  • Bio-Rad Laboratories Inc.
  • bluebird bio, Inc.
  • Bristol-Myers Squibb Company
  • CHIESI Farmaceutici S.p.A.
  • Danaher Corporation
  • Emmaus Medical, Inc.
  • Gamida Cell
  • Medunik USA
  • Novartis AG
  • Prolong Pharmaceuticals, LLC

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Hemoglobinopathies Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Type

  • 6.1 Thalassemia
    • 6.1.1 Market Trends
    • 6.1.2 Key Segments
      • 6.1.2.1 Alpha Thalassemia
      • 6.1.2.2 Beta Thalassemia
    • 6.1.3 Market Forecast
  • 6.2 Sickle Cell Disease
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Others
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast

7 Market Breakup by Treatment

  • 7.1 Blood Transfusion
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Stem-cell Transplantation
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Analgesics
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Antibiotics
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 ACE Inhibitors
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast
  • 7.6 Hydroxyurea
    • 7.6.1 Market Trends
    • 7.6.2 Market Forecast
  • 7.7 Others
    • 7.7.1 Market Trends
    • 7.7.2 Market Forecast

8 Market Breakup by Test Type

  • 8.1 Red Blood Cell (RBC) Count
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Genetic Testing
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 High Performance Liquid Chromatography (HPLC)
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Hemoglobin Isoelectric Focusing (Hb IEF)
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Hemoglobin Electrophoresis (Hb ELP)
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast
  • 8.6 Hemoglobin Solubility Test
    • 8.6.1 Market Trends
    • 8.6.2 Market Forecast

9 Market Breakup by End User

  • 9.1 Hospitals and Clinics
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Diagnostics Laboratories
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Others
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Bio-Rad Laboratories Inc.
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 bluebird bio, Inc.
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 Financials
      • 15.3.2.4 SWOT Analysis
    • 15.3.3 Bristol-Myers Squibb Company
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
      • 15.3.3.4 SWOT Analysis
    • 15.3.4 CHIESI Farmaceutici S.p.A.
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis
    • 15.3.5 Danaher Corporation
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
      • 15.3.5.4 SWOT Analysis
    • 15.3.6 Emmaus Medical, Inc.
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 Financials
    • 15.3.7 Gamida Cell
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
    • 15.3.8 Medunik USA
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 Novartis AG
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 Prolong Pharmaceuticals, LLC
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio

List of Figures

  • Figure 1: Global: Hemoglobinopathies Market: Major Drivers and Challenges
  • Figure 2: Global: Hemoglobinopathies Market: Sales Value (in Billion USD), 2020-2025
  • Figure 3: Global: Hemoglobinopathies Market Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 4: Global: Hemoglobinopathies Market: Breakup by Type (in %), 2025
  • Figure 5: Global: Hemoglobinopathies Market: Breakup by Treatment (in %), 2025
  • Figure 6: Global: Hemoglobinopathies Market: Breakup by Test Type (in %), 2025
  • Figure 7: Global: Hemoglobinopathies Market: Breakup by End User (in %), 2025
  • Figure 8: Global: Hemoglobinopathies Market: Breakup by Region (in %), 2025
  • Figure 9: Global: Hemoglobinopathies (Thalassemia) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 10: Global: Hemoglobinopathies (Thalassemia) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 11: Global: Hemoglobinopathies (Sickle Cell Disease) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 12: Global: Hemoglobinopathies (Sickle Cell Disease) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 13: Global: Hemoglobinopathies (Other Types) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 14: Global: Hemoglobinopathies (Other Types) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 15: Global: Hemoglobinopathies (Blood Transfusion) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 16: Global: Hemoglobinopathies (Blood Transfusion) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 17: Global: Hemoglobinopathies (Stem-cell Transplantation) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 18: Global: Hemoglobinopathies (Stem-cell Transplantation) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 19: Global: Hemoglobinopathies (Analgesics) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 20: Global: Hemoglobinopathies (Analgesics) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 21: Global: Hemoglobinopathies (Antibiotics) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 22: Global: Hemoglobinopathies (Antibiotics) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 23: Global: Hemoglobinopathies (ACE Inhibitors) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 24: Global: Hemoglobinopathies (ACE Inhibitors) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 25: Global: Hemoglobinopathies (Hydroxyurea) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 26: Global: Hemoglobinopathies (Hydroxyurea) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 27: Global: Hemoglobinopathies (Other Treatments) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 28: Global: Hemoglobinopathies (Other Treatments) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 29: Global: Hemoglobinopathies (Red Blood Cell (RBC) Count) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 30: Global: Hemoglobinopathies (Red Blood Cell (RBC) Count) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 31: Global: Hemoglobinopathies (Genetic Testing) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 32: Global: Hemoglobinopathies (Genetic Testing) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 33: Global: Hemoglobinopathies (High Performance Liquid Chromatography-HPLC) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 34: Global: Hemoglobinopathies (High Performance Liquid Chromatography-HPLC) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 35: Global: Hemoglobinopathies (Hemoglobin Isoelectric Focusing-Hb IEF) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 36: Global: Hemoglobinopathies (Hemoglobin Isoelectric Focusing-Hb IEF) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 37: Global: Hemoglobinopathies (Hemoglobin Electrophoresis-Hb ELP) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 38: Global: Hemoglobinopathies (Hemoglobin Electrophoresis-Hb ELP) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 39: Global: Hemoglobinopathies (Hemoglobin Solubility Test) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 40: Global: Hemoglobinopathies (Hemoglobin Solubility Test) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 41: Global: Hemoglobinopathies (Hospitals and Clinics) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 42: Global: Hemoglobinopathies (Hospitals and Clinics) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 43: Global: Hemoglobinopathies (Diagnostics Laboratories) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 44: Global: Hemoglobinopathies (Diagnostics Laboratories) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 45: Global: Hemoglobinopathies (Other End Users) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 46: Global: Hemoglobinopathies (Other End Users) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 47: North America: Hemoglobinopathies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 48: North America: Hemoglobinopathies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 49: United States: Hemoglobinopathies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 50: United States: Hemoglobinopathies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 51: Canada: Hemoglobinopathies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 52: Canada: Hemoglobinopathies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 53: Asia-Pacific: Hemoglobinopathies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 54: Asia-Pacific: Hemoglobinopathies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 55: China: Hemoglobinopathies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 56: China: Hemoglobinopathies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 57: Japan: Hemoglobinopathies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 58: Japan: Hemoglobinopathies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 59: India: Hemoglobinopathies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 60: India: Hemoglobinopathies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 61: South Korea: Hemoglobinopathies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 62: South Korea: Hemoglobinopathies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 63: Australia: Hemoglobinopathies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 64: Australia: Hemoglobinopathies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 65: Indonesia: Hemoglobinopathies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 66: Indonesia: Hemoglobinopathies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 67: Others: Hemoglobinopathies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 68: Others: Hemoglobinopathies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 69: Europe: Hemoglobinopathies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 70: Europe: Hemoglobinopathies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 71: Germany: Hemoglobinopathies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 72: Germany: Hemoglobinopathies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 73: France: Hemoglobinopathies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 74: France: Hemoglobinopathies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 75: United Kingdom: Hemoglobinopathies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 76: United Kingdom: Hemoglobinopathies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 77: Italy: Hemoglobinopathies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 78: Italy: Hemoglobinopathies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 79: Spain: Hemoglobinopathies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 80: Spain: Hemoglobinopathies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 81: Russia: Hemoglobinopathies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 82: Russia: Hemoglobinopathies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 83: Others: Hemoglobinopathies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 84: Others: Hemoglobinopathies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 85: Latin America: Hemoglobinopathies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 86: Latin America: Hemoglobinopathies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 87: Brazil: Hemoglobinopathies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 88: Brazil: Hemoglobinopathies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 89: Mexico: Hemoglobinopathies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 90: Mexico: Hemoglobinopathies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 91: Others: Hemoglobinopathies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 92: Others: Hemoglobinopathies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 93: Middle East and Africa: Hemoglobinopathies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 94: Middle East and Africa: Hemoglobinopathies Market: Breakup by Country (in %), 2025
  • Figure 95: Middle East and Africa: Hemoglobinopathies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 96: Global: Hemoglobinopathies Industry: SWOT Analysis
  • Figure 97: Global: Hemoglobinopathies Industry: Value Chain Analysis
  • Figure 98: Global: Hemoglobinopathies Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Hemoglobinopathies Market: Key Industry Highlights, 2025 and 2034
  • Table 2: Global: Hemoglobinopathies Market Forecast: Breakup by Type (in Million USD), 2026-2034
  • Table 3: Global: Hemoglobinopathies Market Forecast: Breakup by Treatment (in Million USD), 2026-2034
  • Table 4: Global: Hemoglobinopathies Market Forecast: Breakup by Test Type (in Million USD), 2026-2034
  • Table 5: Global: Hemoglobinopathies Market Forecast: Breakup by End User (in Million USD), 2026-2034
  • Table 6: Global: Hemoglobinopathies Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 7: Global: Hemoglobinopathies Market: Competitive Structure
  • Table 8: Global: Hemoglobinopathies Market: Key Players